Text Size

A Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

This study is currently recruiting participants.
Verified February 2012 by University of California, San Diego
Sponsor:
Collaborators:
Celgene Corporation
Pfizer
Information provided by (Responsible Party):
Edward Ball, University of California, San Diego
ClinicalTrials.gov Identifier:
NCT00766116
First received: October 2, 2008
Last updated: February 13, 2012
Last verified: February 2012
History of Changes
  Purpose

This study will test an experimental combination of the drugs Mylotarg and 5-azacitidine in the hopes of finding a treatment that may be effective against Acute Myeloid Leukemia that has come back after treatment.


Condition Intervention Phase
Acute Myeloid Leukemia
 Drug: 5-Azacitidine, Mylotarg
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed AML

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of California, San Diego:

Primary Outcome Measures:
  • In Phase I the Maximum Tolerated Dose will be the maximum dose at which fewer than one-third of patients experience Dose Limiting Toxicity [ Time Frame: approximately 4 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • In Phase II response to the combination treatment of Mylotarg with 5-azacitidine [ Time Frame: Response will be assessed when evaluated at the time the ANC has reached 1000/mm3 for three consecutive days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 36
Study Start Date: July 2005
Estimated Study Completion Date: January 2013
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment Drug: 5-Azacitidine, Mylotarg

A = given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit

M = Mylotarg given 2 times over 2 weeks

Detailed Description:

In the Phase I portion of the study patients with a diagnosis of AML who have relapsed disease will be treated with an assigned number of doses of 5 azacitidine followed by Mylotarg administered two times over two weeks

In the Phase II portion of the study patients will be treated with the dose of 5azacitidine determined to be safe in the Phase I portion of the study followed by Mylotarg.

A sample of blood or bone marrow will be obtained prior to initiation of treatment and another sample obtained after treatment with 5-azacitidine but before Mylotarg and the samples will be tested in the laboratory to determine response to treatment.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Relapsed AML
  • ECOG performance status 0-2, and life expectancy > 3 months
  • ≥ 18 years old
  • Previously untreated for current AML relapse
  • Adequate organ function
  • Written informed consent

Exclusion Criteria:

  • Pregnant or breast-feeding women
  • Growth factors that support platelet or white cell number or function must not have been administered within the past 7 days
  • Currently receiving another investigational drug
  • Currently receiving other anti-cancer agents
  • Uncontrolled infection
  • HIV positive
  • Received previous therapy with either Mylotarg or 5-azacitidine
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00766116

Contacts
Contact: Edward D Ball, MD 858-822-6600 tball@ucsd.edu
Contact: Sue Corringham, RN 858-822-6387 scorringham@ucsd.edu

Locations
United States, California
Stanford University Recruiting
Stanford, California, United States, 94305
Contact: Bruno Medeiros, MD     650-725-3973     brunom@stanford.edu    
Contact: Marlene Zuraek, CRC     650-736-4301     marlenez@stanford.edu    
Principal Investigator: Bruno Medeiros, MD            
United States, Georgia
Northside Hospital/BMTGA Recruiting
Atlanta, Georgia, United States, 30342
Contact: Asad Bashey, MD     404-255-1930     abashey@bmtga.com    
Contact: Nancy McCarthy, RN     404-845-5926     nancy.mccarthy@northside.com    
Principal Investigator: Asad Bashey, MD            
Sponsors and Collaborators
University of California, San Diego
Celgene Corporation
Pfizer
  More Information

No publications provided

Responsible Party: Edward Ball, Professor of medicine, University of California, San Diego
ClinicalTrials.gov Identifier: NCT00766116     History of Changes
Other Study ID Numbers: 090516
Study First Received: October 2, 2008
Last Updated: February 13, 2012
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by University of California, San Diego:
AML

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Neoplasms by Histologic Type
Neoplasms
Azacitidine
Gemtuzumab
 Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Enzyme Inhibitors

ClinicalTrials.gov processed this record on May 21, 2013